New hope for AML patients: drug combo targets leukemia cells

NCT ID NCT04742101

Completed Disease control Sponsor: Institut de Recherches Internationales Servier Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called S65487, which blocks a protein that helps leukemia cells survive, combined with the standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. Researchers aimed to find the safest dose and see if the combination could lead to complete remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: S65487 (a Bcl2 inhibitor) combined with azacitidine
What this could lead to: If successful, this combination could offer a new treatment option for older or frail adults with acute myeloid leukemia who cannot tolerate intensive chemotherapy.
What could go wrong: This is an early-phase trial with only 57 participants, so results may not apply to all patients. The drug combination may cause side effects or fail to improve remission rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

C. Universidad de Navarra Servicio de Hematologia

Pamplona, 31008, Spain
H. Universitario La Fe Servicio de Hematologia

Valencia, 46026, Spain
Hospital 12 de Octubre Servicio de Hematología

Madrid, 28041, Spain
Institut Gustave Roussy

Villejuif, 94805, France
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie Klinika Transplantacji Szpiku i Onkohematologii pokoj 4.041 ul. Wybrzeze Armii Krajowej 15

Gliwice, 44-102, Poland
Samsung Medical Center - Division of Hematology-Oncology

Seoul, 06351, South Korea
Semmelweis Egyetem Belgyógyászati és Onkológiai Klinika Klinikai Farmakológiai Részleg

Budapest, H-1083, Hungary
Seoul National University Hospital - Department of Hematology-Oncology

Seoul, 03080, South Korea
The Christie NHS foundation Trust

Manchester, M20 4BX, United Kingdom
University College London - Hospitals NHS Foundation Trust

London, NW1 2PG, United Kingdom
Western General Hospital

Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.